Vivo Bio Tech Share Price

Vivo Bio Tech Limited, with its corporate operations in Hyderabad, functions as a pre‑clinical contract research organization (CRO) in India. The company was incorporated in 1987 and was formerly known as Sunshine Factors & Exports Limited before changing its name to Vivo Bio Tech Limited in September 2002. Vivo Bio Tech offers comprehensive drug development and discovery services to pharmaceutical and biotech companies worldwide, with services spanning in‑vivo and in‑vitro toxicity studies, pharmacological investigations, pharmacokinetic and toxicokinetic studies, genotoxicity screening, and analytical services. The company also supplies specific pathogen-free (SPF) lab animals, breeds and distributes rodent models, and provides lab animal diets, serving a customer base of over 400 firms globally.

Vivo Bio Tech share price on NSE and BSE signifies how market participants react to the company’s operational performance and the overall developments in the contract research sector. The company’s financial health depends on client order volumes from pharmaceutical companies, regulatory approval cycles for drug discovery programs, capacity utilisation of its 150,000 sq. ft. pre‑clinical research centre, export service demand, and the performance of its service portfolio spanning toxicology, pharmacology and analytical segments. Vivo Bio Tech stock price is shaped by various factors such as earnings reports, regulatory changes in clinical research guidelines, global pharmaceutical R&D spending trends, and competition from larger CRO players. In the longer run, strategies such as expanding into new therapeutic areas, upgrading laboratory infrastructure, and deepening relationships with global pharma companies affect the stock market sentiments.

Vivo Bio Tech live share price provides real‑time information about the last price traded, bid and ask prices, and volume traded on the BSE exchange. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and healthcare sector news. Constant monitoring of the Vivo Bio Tech live price helps in observing short term price volatility and shows how the stock moves relative to the broader healthcare index. Furthermore, monitoring Vivo Bio Tech share price movements helps investors understand real‑time market sentiment, price fluctuations, and trading behaviour.

Vivo Bio Tech stock price movements allow market participants to evaluate short‑term performance and respond to news, quarterly results, or sector trends that may influence the company’s valuation and overall investment outlook. The company operates its research and development activities primarily from its headquarters in Hyderabad, Telangana, with a strong presence across the pharmaceutical research ecosystem. Vivo Bio Tech continues to focus on pre‑clinical CRO services, SPF lab animal supply, and custom model development as its core business segments, adopting business models that generate required returns while maintaining scientific excellence and regulatory compliance.

Vivo Bio Tech Limited Company Fundamentals

a. Company Background

Vivo Bio Tech Limited was incorporated in 1987 and is engaged in the provision of drug development and discovery services to pharmaceutical and biotech companies worldwide. The company operates primarily in the contract research segment, supplying services such as in‑vivo and in‑vitro toxicity studies, pharmacological investigations, pharmacokinetic and toxicokinetic studies, genotoxicity screening, and analytical services. Its research operations are based in India, with an advanced 150,000 sq. ft. pre‑clinical research centre located in Hyderabad, Telangana, while corporate functions are managed from its administrative offices in Hyderabad. Over time, the company has expanded its service portfolio to include SPF lab animal supply, custom rodent model breeding, stem cell products, lab animal diets, regulatory and non‑regulatory IND enabling preclinical development services, and syngeneic or xenograft models for anti‑cancer agent evaluation. Financial performance is assessed through standard metrics such as revenue growth, operating margins, and client acquisition rates. Market valuation indicators such as the P/E ratio are used by analysts for comparative assessment within the contract research sector. Overall fundamentals are influenced by pharmaceutical R&D spending cycles, regulatory approval timelines, raw material availability for lab animal breeding, and input cost fluctuations.

b. Company Product Lines

• In‑vivo and In‑vitro Toxicity Studies
  o Assesses the safety profile of drug candidates through animal‑based and cell‑based testing protocols for pharmaceutical clients.
• Pharmacological Investigations
  o Evaluates the therapeutic effects and mechanisms of action of new chemical entities across various disease models.
• Pharmacokinetic and Toxicokinetic Studies
  o Measures how the body absorbs, distributes, metabolises and excretes drug candidates in both rodent and non‑rodent animal models.
• Genotoxicity Screening
  o Identifies potential genetic damage caused by drug candidates through specialized laboratory assays.
• Analytical Services
  o Provides chemical analysis, method development and validation for pharmaceutical research and development programs.
• SPF Lab Animals
  o Supplies specific pathogen free mice, rats and guinea pigs bred under controlled conditions for research purposes.
• Lab Animal Diets
  o Offers nutritionally formulated diets for laboratory animals used in research and breeding facilities.
• Custom Rodent Models
  o Breeds and distributes custom rodent models tailored to specific research requirements of pharmaceutical clients.
• Regulatory and Non‑regulatory IND Preclinical Development Services
  o Supports Investigational New Drug applications through comprehensive preclinical safety and efficacy studies.
• Syngeneic or Xenograft Models for Anti‑cancer Agent Evaluation
  o Designs and develops tumour models for evaluating the effectiveness of potential cancer treatments.

The service portfolio is structured to serve both domestic pharmaceutical companies and international biotech clients across global markets.

c. Company Revenue Model

• Contract Research Services Revenue
  o Income generated through fees charged to pharmaceutical and biotech companies for conducting toxicity studies, pharmacological investigations, pharmacokinetic studies, genotoxicityscreening and analytical services.
• Lab Animal and Product Sales
  o Revenue from supplying SPF lab animals, lab animal diets, stem cell products and related research materials to research institutions and pharmaceutical companies.
• Custom Model Development Revenue
  o Earnings from breeding and distributing custom rodent models and developing syngeneic or xenograft models for oncology research.
• Regulatory Services Revenue
  o Fees from providing IND enabling preclinical development services and regulatory support for drug approval applications.

Revenue performance is primarily influenced by global pharmaceutical R&D spending, client order book from domestic and international customers, lab animal breeding volumes, and service pricing realizations in domestic and export markets.

d. Geographic Presence

• Registered Office
  o Hyderabad, Telangana, India.
• Corporate Headquarters
  o Hyderabad, Telangana, India.
• Research Facility
  o Pre‑clinical research centre located at Hyderabad, Telangana, India.
• Distribution Network
  o Domestic supply across India through direct contracts with pharmaceutical companies and research institutions.
• Export Markets
  o Services and products supplied to pharmaceutical and biotech companies in international markets depending on client demand.

e. Key Milestones

• 1987: Incorporation of Sunshine Factors & Exports Limited.
• 2002: Name changed from Sunshine Factors & Exports Limited toVivo Bio Tech Limited in September.
• 2004: Registered office shifted from Ahmedabad to Hyderabad.
• 2013: Became wholly‑owned subsidiary of Pranda Group.
• 2014: Transfer of ownership to Kalyan Ram Mangipudi, Sri Kalyan Kompella and Viswanath Kompella.
• 2017: Raised funds through preferential allotment of convertible warrants.
• 2021: Expansion of 150,000 sq. ft. pre‑clinical research centre.
• Recent years: Continued focus on building global CRO capabilities, upgrading laboratory infrastructure, and deepening relationships with international pharmaceutical clients.

f. Industry Perspective

The contract research organization (CRO) industry is capital‑intensive and closely linked to pharmaceutical and biotechnology for R&D spending, drug discovery programs, and regulatory approval cycles. Demand trends are influenced by global healthcare expenditure, patent expiries of blockbuster drugs, growth in outsourced drug development, and increasing complexity of clinical trials. The industry is also affected by fluctuations in lab animal costs, consumables pricing, regulatory changes introduced by bodies such as the US FDA and Indian CDSCO, and competition from large multinational CROs. Scientific advancements in personalized medicine, biologics, and gene therapy are increasingly shaping service capabilities and capital investment decisions. Companies in the sector must manage project execution timelines, maintain quality certifications such as OECD GLP, and adhere to animal welfare regulations while delivering reliable study data. These factors collectively influence financial performance and investor perception of firms like Vivo Bio Tech.

Vivo Bio Tech Limited Stock Market Presence: Listings & Index Representation

Vivo Bio Tech Limited is listed on the Bombay Stock Exchange (BSE) under the scrip code 511509. Vivo Bio Tech share price is actively traded on the BSE platform under the symbol VIVOBIOT. The company is not listed on the National Stock Exchange (NSE). Vivo Bio Tech stock price is available for trading exclusively on the BSE exchange with a face value of Rs 10 per share. The company’s market presence is within the small‑cap segment of the market, specifically under the biotechnology and pharmaceutical research industry. Due to its size and sector focus, Vivo Bio Tech share price is generally tracked by investors interested in the contract research and life sciences sector.

Vivo Bio Tech finds representation in broad‑based stock market indices that track the healthcare and biotechnology sector. The company forms a constituent of the BSE SmallCap index within the pharmaceuticals and biotechnology category. Vivo Bio Tech also forms part of sector‑specific indices that monitor biotechnology and life sciences companies. Vivo Bio Tech movement relative to these indices provides context for understanding the company’s market standing. This presence helps investors track the stock relative to other contract research and biotechnology companies operating in the Indian market. The company’s inclusion in these indices underscores its presence within the broader pharmaceutical research ecosystem.

Vivo Bio Tech Limited Stock Performance and Share Price History

Vivo Bio Tech share price today on the BSE reflects its position as a pre‑clinical contract research organization serving pharmaceutical and biotech companies in India and globally. Its performance is qualitatively driven by factors such as client order book from drug discovery programs, management of lab animal breeding and operating costs, growth in international client acquisitions, and the ability to control research and administrative expenses. Investors compare the stock’s current movement with other CRO and biotechnology companies to assess relative strength. Vivo Bio Tech movements become visible through real market movements across different time periods.

Vivo Bio Tech shows patterns during earnings‑driven price changes. Broader sector strength has also supported the stock from time to time. Beyond operational and sector influences, corporate actions such as the company’s contract wins, its expansion of the Hyderabad research facility, and its strategic focus on building a global CRO presence can significantly affect Vivo Bio Tech movements by shaping future growth expectations. This shows how strategic initiatives may trigger short‑term swings, even within a regulatory environment shaped by global pharmaceutical R&D cycles and clinical research guidelines.

While short‑term movements respond to events and announcements, longer‑term valuation trends are captured by the stock’s annual high and low levels, offering context beyond daily or weekly changes. A notable peak in Vivo Bio Tech indicates stronger global pharma R&D spending and stable margins, whereas a significant low aligns with market corrections or healthcare sector volatility. These extremes reflect the impact of regulatory policies, global pharmaceutical research trends, and earnings visibility, providing a framework for understanding historical performance of Vivo Bio Tech.

Vivo Bio Tech behaviour mirrors the trading patterns of a small‑cap contract research organization within India’s life sciences ecosystem. The company’s diversified service portfolio spanning toxicity studies, pharmacological investigations, pharmacokinetic studies, genotoxicity screening, analytical services, and lab animal supply has shaped its price history. Over the past five years, Vivo Bio Tech has experienced periods of sharp gains followed by phases of consolidation. For instance, it delivered positive annual returns in certain years but recorded negative returns in other years, underperforming the broader small‑cap index over various time horizons. Vivo Bio Tech has shown higher volatility compared to the overall market.

The company’s performance has closely tracked global pharmaceutical R&D spending and drug discovery activity cycles. Positive momentum for Vivo Bio Tech appeared during periods of increased outsourcing of preclinical research by pharmaceutical companies and growth in oncology drug development programs. However, periods of high operating costs and competitive pressure from larger multinational CROs have led to consolidation in Vivo Bio Tech. Profitability has faced challenges due to variable project revenue recognition and cost structures, highlighting the cyclical nature of the contract research industry. Vivo Bio Tech stock price has reflected these challenges through periods of correction.

Vivo Bio Tech experienced a notable decline during challenging market conditions. A drop in client orders from pharmaceutical companies or delays in regulatory approval cycles directly impacts revenue and leads to selling pressure, which pulls Vivo Bio Tech lower. Changes in government policy such as adjustments in animal welfare regulations or updates to clinical research guidelines can also cause the stock to fall. Moreover, increases in operating costs without corresponding increases in service pricing squeeze margins, making Vivo Bio Tech share price less attractive to market participants.

Periods of global economic slowdown that affect pharmaceutical R&D budgets raise concerns about outsourcing volumes, leading to price declines in Vivo Bio Tech. Vivo Bio Tech is sensitive to lab animal cost movements and consumables pricing. If input costs rise significantly, it can cause the stock to fall as investors adjust expectations for future margin growth. Broader market sell‑offs in small cap stocks also pull Vivo Bio Tech share price down, regardless of the company’s individual performance.

Lower project volumes or reduced client acquisitions directly impacts revenue, resulting in a lower valuation for Vivo Bio Tech. The company has faced headwinds from increased competitive pressures in the CRO market from larger international players with greater scale and broader capabilities. Vivo Bio Tech has also been affected by the company’s need to continually invest in laboratory upgrades and maintain quality certifications such as OECD GLP compliance to remain competitive. The company has experienced fluctuations in quarterly net profit, with net profit declining significantly in recent periods compared to the same quarters of prior years, reflecting the volatile nature of the CRO business.

The company maintains a strong focus on its core CRO service offerings while exploring opportunities to expand into new therapeutic areas and deepen relationships with global pharmaceutical clients. Vivo Bio Tech has shown that the company’s strategy of serving both domestic and international clients with a comprehensive suite of preclinical services has provided growth opportunities during favourable R&D cycles. However, the competitive landscape and the presence of larger multinational CROs with significant scale advantages continue to influence Vivo Bio Tech share price movements. Vivo Bio Tech stock price remains closely watched by market participants for signals about pharmaceutical R&D spending trends and order book growth.

Vivo Bio Tech Limited Investor Relevance and Role in Portfolio

Vivo Bio Tech share price is relevant for investors seeking exposure to the contract research sector with a focus on pre‑clinical drug development and laboratory animal services. The company’s inclusion in small‑cap and healthcare indices underscores its importance in India’s pharmaceutical research ecosystem. Vivo Bio Tech position as a comprehensive pre‑clinical CRO with a 150,000 sq. ft. advanced research facility, together with its diversified service portfolio spanning toxicity studies, pharmacology, pharmacokinetics, genotoxicity screening, analytical services, and SPF lab animal supply, makes it a consideration for certain portfolio allocations.

Vivo Bio Tech share price is influenced by the company’s ownership structure. The company’s equity is held by a mix of promoters, corporate bodies, and retail investors, reflecting its standing in India’s biotechnology sector. Promoters hold a stable majority stake of 35.43 percent, reflecting significant internal control under the current management. Foreign institutional investors hold no shares in the company. Domestic institutional investors hold no shares in Vivo Bio Tech. Mutual funds hold no stake in the company. Insurance companies and banks hold no shares in the company. The public holds the remaining stake of 64.57 percent, including retail investors and other entities. The company’s management includes Dr. Alangudi Sankaranarayanan as Chief Executive Officer, President and Whole Time Director, Sri Kalyan Kompella as Whole Time Director, Head of Operations and Chief Financial Officer, and Kalyan Ram Mangipudi as Whole Time Director. Promoters have pledged none of their holdings, indicating no pledge risk. This investor base, with stable promoter participation and no institutional holdings, underscores the company’s role as a holding in focused portfolios concentrating on small‑cap contract research services.

Beyond fundamentals and ownership, Vivo Bio Tech stock price is actively monitored in cash market segments on the BSE exchange. Trading volumes and delivery patterns reflect expectations on pharmaceutical R&D spending, client order inflows, and regulatory policy actions. The stock is available for trading on the BSE exchange, allowing investors to take positions based on their outlook for the CRO sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements from drug regulatory authorities.

Technical indicators provide additional insight into short term momentum shifts in Vivo Bio Tech share price. While these indicators are primarily used for near term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short term and weekly timeframe, the stock has exhibited price movements that correlate with broader healthcare sector trends. Based on available data, the stock’s beta indicates its volatility characteristics relative to the broader market, suggesting that Vivo Bio Tech share price movements may have certain correlation patterns with the overall index.

Overall, Vivo Bio Tech share price demonstrates a volatility profile that makes it sensitive to broader market movements and sector specific factors such as global pharmaceutical R&D spending cycles, regulatory changes affecting clinical research, lab animal and consumables cost fluctuations, and competitive dynamics in the CRO industry. The company’s debt to equity ratio reflects its use of leverage in funding its laboratory infrastructure and working capital needs. Return on equity and return on capital employed are measured at certain levels, and the company’s book value per share serves as a reference point for valuation assessments by market participants.

Vivo Bio Tech Limited Sectoral Relevance and Peer Positioning

Vivo Bio Tech Limited sector relevance stems from its three‑decade presence in the contract research industry, its position as a comprehensive pre‑clinical CRO providing drug development and discovery services to pharmaceutical and biotech companies worldwide, its service portfolio including in‑vivo and in‑vitro toxicity studies, pharmacological investigations, pharmacokinetic and toxicokinetic studies, genotoxicity screening, and analytical services, its supply of SPF lab animals, breeding and distribution of rodent models, custom model generation, stem cell products, and lab animal diets, its regulatory and non‑regulatory IND enabling preclinical development services, its design and development of syngeneic or xenograft models for anti‑cancer agent evaluation, its customer base of 400 firms across various sectors with over 150 active clients, its advanced 150,000 sq. ft. pre‑clinical research centre in Hyderabad, its support of biomedical research through accessible specific pathogen‑free animals and diets via global partnerships, and its mission to solve customer research problems through collaboration with global firms using cutting‑edge science, establishing it as a focused small‑cap CRO provider supporting India’s pharmaceutical research ecosystem. Vivo Bio Tech share price is compared with peers like Dishman Carbogen Amcis, Vimta Labs, Windlas Biotech, Shree Ganesh Remedies, Zenotech Laboratories, Sotac Pharmaceuticals, and Krebs Biochemicals. These comparisons focus on service portfolio composition, laboratory infrastructure, client relationships, and quality certifications rather than short‑term stock moves. These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of global pharmaceutical R&D spending trends, drug approval cycles, and government clinical research policies further highlights Vivo Bio Tech positioning within India’s broader contract research market.

Vivo Bio Tech market cap reflects its position as a small‑cap player within India’s contract research sector. Based on available data, the company’s market capitalization fluctuates within a range depending on the reporting period. The market cap has moved in line with investor perceptions of the company’s growth potential following various market cycles. From earlier years through more recent periods, the market cap showed certain trends as the company expanded its research facility and strengthened its client relationships, followed by periods of correction. This pattern reflects investor confidence during favourable pharmaceutical R&D cycles, followed by contraction during challenging periods impacted by rising operating costs and competitive pressures from larger CRO players. This movement mirrors the pattern in Vivo Bio Tech share price from its various levels over time.

Vivo Bio Tech earnings trajectory demonstrates the impact of its operational execution in a competitive contract research industry. In recent fiscal years, total income showed certain trends supported by the core CRO services business. Based on available data, the company’s revenue from operations showed growth in some periods and modest increases in others. However, net profit after tax has shown significant variability across quarters, with recent quarterly net profit declining sharply compared to the same quarter of the previous year. The company has faced headwinds from fluctuating client order volumes, increased competitive pressures from larger multinational CROs, and the need to maintain quality certifications and regulatory compliance. However, the company has continued to focus on its core CRO services business and expects to maintain its presence in domestic and international markets. These developments illustrate the cyclical nature of the contract research industry and the company’s position within this sector. Vivo Bio Tech share price has moved in response to these earnings patterns.

Vivo Bio Tech EPS provides insight into its operational performance and income generation from contract research services, lab animal product sales, custom model development, and regulatory services. Based on available data, the company reported a basic EPS in certain recent quarters showing certain patterns compared to previous periods. The trailing twelve month EPS stands at a certain level. The company’s EPS for the last full fiscal year showed a certain trend compared to the prior fiscal year. The company has a face value per share of Rs 10 and is promoted by the current management group. More recent quarterly performance suggests that EPS has shown certain movements as the company manages its revenue growth and operational costs. Vivo Bio Tech share price has reflected these EPS trends over time.

Vivo Bio Tech P/E ratio reflects how investors perceive the company’s earnings relative to its revenue streams from contract research services, lab animal supply, custom model development, and regulatory services. Based on available data, the current P/E ratio stands at a certain level relative to the industry average. The company’s profit after tax showed certain changes from previous fiscal years to more recent periods. However, quarterly performance has shown certain patterns, with profit after tax and total income showing changes on a quarter on quarter basis. The company’s earnings before interest and taxes for recent periods stood at certain levels with corresponding margins. The net profit margin showed certain changes in recent quarters compared to earlier periods. Overall, these changes highlight how market sentiment evolves alongside the company’s operational performance in a cyclical industry. Vivo Bio Tech stock price has moved in line with these valuation changes.

Summary

Vivo Bio Tech operates as a small‑cap pre‑clinical contract research organization serving pharmaceutical and biotech companies in India and global markets. Vivo Bio Tech share price movements reflect the company’s client order volumes and pharmaceutical R&D spending trends. Vivo Bio Tech stock price is influenced by regulatory policies in clinical research, lab animal cost cycles, and competitive dynamics in the CRO industry. The company operates a 150,000 sq. ft. advanced research centre in Hyderabad and serves over 150 active clients. Promoters hold a stable majority stake of about 35.43 percent in the company.